33629536 34740705 31813574 34560015 32918399 33006093 34352720 32025600 34815553 33396949 35433529 34621052 35589249 32128921 32451628 35089884 35014145 31959644 32241197 35468325 33381677 34166721 33302841 33467660 32712221 - Search Results

Year	Number of Results
2019	1
2020	11
2021	10
2022	7

1

Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial.

Amerikanou C, Kanoni S, Kaliora AC, Barone A, Bjelan M, D'Auria G, Gioxari A, Gosalbes MJ, Mouchti S, Stathopoulou MG, Soriano B, Stojanoski S, Banerjee R, Halabalaki M, Mikropoulou EV, Kannt A, Lamont J, Llorens C, Marascio F, Marascio M, Roig FJ, Smyrnioudis I, Varlamis I, Visvikis-Siest S, Vukic M, Milic N, Medic-Stojanoska M, Cesarini L, Campolo J, Gastaldelli A, Deloukas P, Trivella MG, Francino MP, Dedoussis GV; MAST4HEALTH consortium. Amerikanou C, et al. Mol Nutr Food Res. 2021 May;65(10):e2001178. doi: 10.1002/mnfr.202001178. Epub 2021 Apr 16. Mol Nutr Food Res. 2021. PMID: 33629536 Clinical Trial.

2

EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.

Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. Ratziu V, et al. J Hepatol. 2022 Mar;76(3):506-517. doi: 10.1016/j.jhep.2021.10.018. Epub 2021 Nov 3. J Hepatol. 2022. PMID: 34740705 Free article.

3

Predicting NASH response with liver fat: Are we back to square one?

Wong VW. Wong VW. J Hepatol. 2020 Mar;72(3):386-388. doi: 10.1016/j.jhep.2019.10.024. Epub 2019 Dec 6. J Hepatol. 2020. PMID: 31813574 No abstract available.

4

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, Hallakou-Bozec S, Bolze S, Grouin JM, Jeannin Megnien S, Dubourg J, Ratziu V. Cusi K, et al. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):889-902. doi: 10.1016/S2468-1253(21)00300-9. Epub 2021 Sep 22. Lancet Gastroenterol Hepatol. 2021. PMID: 34560015 Clinical Trial.

5

Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.

Romualdo GR, Da Silva TC, de Albuquerque Landi MF, Morais JÁ, Barbisan LF, Vinken M, Oliveira CP, Cogliati B. Romualdo GR, et al. Environ Toxicol. 2021 Feb;36(2):168-176. doi: 10.1002/tox.23021. Epub 2020 Sep 12. Environ Toxicol. 2021. PMID: 32918399

6

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. Eslam M, et al. Hepatol Int. 2020 Dec;14(6):889-919. doi: 10.1007/s12072-020-10094-2. Epub 2020 Oct 1. Hepatol Int. 2020. PMID: 33006093

7

Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome.

Albert SG, Wood EM. Albert SG, et al. Diabetes Metab Syndr. 2021 Sep-Oct;15(5):102232. doi: 10.1016/j.dsx.2021.102232. Epub 2021 Jul 28. Diabetes Metab Syndr. 2021. PMID: 34352720

8

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?

Noureddin N, Schattenberg JM, Alkhouri N, Noureddin M. Noureddin N, et al. Hepatol Commun. 2020 Feb 3;4(2):141-144. doi: 10.1002/hep4.1473. eCollection 2020 Feb. Hepatol Commun. 2020. PMID: 32025600 Free PMC article. No abstract available.

9

Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.

Tamaki N, Ajmera V, Loomba R. Tamaki N, et al. Nat Rev Endocrinol. 2022 Jan;18(1):55-66. doi: 10.1038/s41574-021-00584-0. Epub 2021 Nov 23. Nat Rev Endocrinol. 2022. PMID: 34815553 Free PMC article. Review.

10

Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.

Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G. Mantovani A, et al. Metabolites. 2020 Dec 30;11(1):22. doi: 10.3390/metabo11010022. Metabolites. 2020. PMID: 33396949 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results